Hepatology research : the official journal of the Japan Society of Hepatology · 2026
Indoleamine 2,3-Dioxygenase 1 as an Adjunctive Histopathological Marker of Cholangitis Activity in Primary Biliary Cholangitis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yoshimura Kaori, Shimoda Shinji, Masuda Ryoka, Thi Tram Nguyen, Yang Rui, Thi Quynh Nguyen, Le Thanh Dong, Tamano Yuko, Sato Yasunori, Yamashita Taro, Harada Kenichi
Аннотация
AIM: To investigate the expression and clinicopathological significance of indoleamine 2,3-dioxygenase 1 (IDO-1) in primary biliary cholangitis (PBC), particularly its potential role as an adjunctive histopathological marker for diagnosis in early or atypical cases and as an indicator of disease activity.
METHODS: We retrospectively analyzed 83 liver biopsy specimens from patients clinically diagnosed with or suspected of having PBC between 2016 and 2025. IDO-1 expression in interlobular bile ducts was assessed by immunohistochemistry and correlated with clinical, biochemical, and histological features, including a new histological staging and grading system for PBC. Statistical analyses included univariate and multivariate logistic regression, and a subgroup analysis was performed for patients receiving ursodeoxycholic acid (UDCA).
RESULTS: IDO-1 was expressed in 64 of 83 cases (77.1%). Our multivariate analysis identified UDCA treatment (OR = 0.105, 95% CI: 0.0138-0.794, p = 0.029) and the cholangitis activity (CA) score (OR = 2.91, 95% CI: 1.18-7.18, p = 0.021) as independent predictors of IDO-1 expression. IDO-1 positivity was significantly reduced in UDCA-treated patients (50.0%) compared with untreated patients (95.9%, p < 0.0001). In the UDCA subgroup, unlike other histological features, IDO-1 expression remained significantly associated with higher CA scores.
CONCLUSIONS: IDO-1 reflects active cholangitis rather than chronic damage such as fibrosis or bile duct loss. It is a sensitive marker of dynamic immune activity that may serve as an adjunctive histopathological marker.
METHODS: We retrospectively analyzed 83 liver biopsy specimens from patients clinically diagnosed with or suspected of having PBC between 2016 and 2025. IDO-1 expression in interlobular bile ducts was assessed by immunohistochemistry and correlated with clinical, biochemical, and histological features, including a new histological staging and grading system for PBC. Statistical analyses included univariate and multivariate logistic regression, and a subgroup analysis was performed for patients receiving ursodeoxycholic acid (UDCA).
RESULTS: IDO-1 was expressed in 64 of 83 cases (77.1%). Our multivariate analysis identified UDCA treatment (OR = 0.105, 95% CI: 0.0138-0.794, p = 0.029) and the cholangitis activity (CA) score (OR = 2.91, 95% CI: 1.18-7.18, p = 0.021) as independent predictors of IDO-1 expression. IDO-1 positivity was significantly reduced in UDCA-treated patients (50.0%) compared with untreated patients (95.9%, p < 0.0001). In the UDCA subgroup, unlike other histological features, IDO-1 expression remained significantly associated with higher CA scores.
CONCLUSIONS: IDO-1 reflects active cholangitis rather than chronic damage such as fibrosis or bile duct loss. It is a sensitive marker of dynamic immune activity that may serve as an adjunctive histopathological marker.